| 000 | 01897 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517105848.0 | ||
| 264 | 0 | _c20170807 | |
| 008 | 201708s 0 0 eng d | ||
| 022 | _a1524-4563 | ||
| 024 | 7 |
_a10.1161/HYPERTENSIONAHA.116.07480 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNishizawa, Keitaro | |
| 245 | 0 | 0 |
_aChronic Treatment With an Erythropoietin Receptor Ligand Prevents Chronic Kidney Disease-Induced Enlargement of Myocardial Infarct Size. _h[electronic resource] |
| 260 |
_bHypertension (Dallas, Tex. : 1979) _c09 2016 |
||
| 300 |
_a697-706 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aErythropoietin _xpharmacology |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolome |
| 650 | 0 | 4 |
_aMyocardial Infarction _xetiology |
| 650 | 0 | 4 |
_aMyocardial Reperfusion Injury _xprevention & control |
| 650 | 0 | 4 | _aNephrectomy |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xpharmacology |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xdrug effects |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aReference Values |
| 650 | 0 | 4 |
_aRenal Insufficiency, Chronic _xcomplications |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 700 | 1 | _aYano, Toshiyuki | |
| 700 | 1 | _aTanno, Masaya | |
| 700 | 1 | _aMiki, Takayuki | |
| 700 | 1 | _aKuno, Atsushi | |
| 700 | 1 | _aTobisawa, Toshiyuki | |
| 700 | 1 | _aOgasawara, Makoto | |
| 700 | 1 | _aMuratsubaki, Shingo | |
| 700 | 1 | _aOhno, Kouhei | |
| 700 | 1 | _aIshikawa, Satoko | |
| 700 | 1 | _aMiura, Tetsuji | |
| 773 | 0 |
_tHypertension (Dallas, Tex. : 1979) _gvol. 68 _gno. 3 _gp. 697-706 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/HYPERTENSIONAHA.116.07480 _zAvailable from publisher's website |
| 999 |
_c26264205 _d26264205 |
||